B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 190.15 DKK -1.43% Market Closed
Market Cap: 15B DKK
Have any thoughts about
Bavarian Nordic A/S?
Write Note

Relative Value

The Relative Value of one BAVA stock under the Base Case scenario is 242.99 DKK. Compared to the current market price of 190.15 DKK, Bavarian Nordic A/S is Undervalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAVA Relative Value
Base Case
242.99 DKK
Undervaluation 22%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
77
vs Industry
79
Median 3Y
3.5
Median 5Y
6.6
Industry
7.6
Forward
2.7
vs History
23
vs Industry
9
Median 3Y
9.4
Median 5Y
9.4
Industry
22.1
Forward
17.7
vs History
49
vs Industry
12
Median 3Y
6.9
Median 5Y
7.7
Industry
21.9
vs History
9
vs Industry
8
Median 3Y
-12.6
Median 5Y
-8.7
Industry
23.4
vs History
74
vs Industry
53
Median 3Y
1.6
Median 5Y
2.1
Industry
2.5
vs History
77
vs Industry
70
Median 3Y
3.2
Median 5Y
6.6
Industry
7.5
Forward
2.3
vs History
77
vs Industry
64
Median 3Y
5.3
Median 5Y
18
Industry
9.3
vs History
49
vs Industry
11
Median 3Y
6.6
Median 5Y
6.9
Industry
4.2
Forward
8.2
vs History
23
vs Industry
8
Median 3Y
5.7
Median 5Y
5.7
Industry
4
Forward
13.8
vs History
49
vs Industry
13
Median 3Y
5.8
Median 5Y
6.6
Industry
5.9
vs History
15
vs Industry
8
Median 3Y
-9.9
Median 5Y
-10.4
Industry
3.9
vs History
73
vs Industry
56
Median 3Y
1.4
Median 5Y
1.6
Industry
4.5

Multiples Across Competitors

BAVA Competitors Multiples
Bavarian Nordic A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Bavarian Nordic A/S
CSE:BAVA
14.8B DKK 2.4 21 6.7 17.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
311.8B USD 5.6 61.5 15.3 23.5
US
Amgen Inc
NASDAQ:AMGN
140.7B USD 4.3 33.4 16 30.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 4.1 921.1 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD 9.7 -215.1 21.1 22.2
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD 5.6 16.8 15.2 16.9
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.6 -109.5 -79.8
P/S Multiple
Revenue Growth P/S to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/S: 3 457 240.2
2.4
-23%
N/A
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.3
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/E: 180.9
21
-36%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.5
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.4
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
921.1
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -215.1
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBITDA: 14.9
6.7
-41%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.1
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBIT: 20.7
17.5
-42%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.2
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.8 N/A N/A

See Also

Discover More
Back to Top